According to a statement from the Champalimaud Foundation, the consortium will bring together teams of researchers from Portugal, the United Kingdom, France, Germany, Italy, Ireland, Saudi Arabia, Sudan and the United States, combining clinical research in cancer and infectious diseases.
In addition to the Champalimaud Foundation, the partnership also includes UCL London, the French Institute Gustave Roussy, the Center for Experimental Medicine at Queen’s University in Belfast and the Center for Infectious Diseases in Rome, among others.
The foundation says that for the first time centers for cancer and infectious diseases are working together on clinical developments with the aim of changing the course of covid-19.
Clinical immunology is at a crossroads where biologically and clinically relevant research intersects clinical practice in infectious diseases and cancer, although there is often no cross-interface between these disciplines.
The consortium is open to the participation of other participants who subscribe to the sharing of knowledge of specialized research, as well as the active promotion of promising clinical concepts. A web page is soon to be made available, where information on projects, organizations involved and indications on how to other entities can join this initiative.